Viatris AI Adoption Tracker
Last updated: August 9, 2026
Overview
Viatris Inc. is a global pharmaceutical company formed in 2020 through the merger of Mylan and Pfizer's Upjohn division, positioned as a bridge between generics and brands [1]. While the company has not prominently featured AI in its public communications or earnings calls, it has begun exploring AI-driven collaborations and digital transformation initiatives [2]. In October 2025, Viatris partnered with Locus Biosciences to develop AI-powered bacteriophage therapies for ophthalmic infections, marking its first significant AI-focused initiative [3]. The company has also pursued digital transformation, particularly during the COVID-19 pandemic, under CIO Ramkumar Rayapureddy's leadership [4]. However, Viatris appears to be in the early stages of AI adoption compared to other pharmaceutical companies, with most initiatives focused on operational efficiency rather than transformative AI applications.
AI Maturity Index
Radar Comparison
Peer Comparison: Viatris vs healthcare
Based on 66 companies in sector
| Dimension | Viatris | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 2.0 | 3.7 | -1.7 |
| Proficiency | 2.0 | 3.5 | -1.5 |
| Impact | 1.0 | 3.6 | -2.6 |
| Overall | 1.6 | 3.6 | -2.0 |
AI Hiring Signals
Viatris Job Postings Analysis
Tech vs Non-Tech AI Requirements
Non-tech AI adoption exceeds tech roles - strong org-wide AI fluency signal
Top Departments by AI Mention Rate
Analysis
AI skills are increasingly expected across the organization, with 15% of all job postings mentioning AI. Notably, non-tech roles show higher AI requirements at 18% compared to tech roles at 8.3%, particularly in Marketing (50%) and Product (33%), suggesting strong organizational AI fluency expectations beyond traditional technical functions.
View Sample Job Postings (8 sources)
Key Metrics
AI Initiatives
AI-Driven Bacteriophage Therapy Collaboration with Locus Biosciences
October 2025
Research collaboration to develop precision engineered bacteriophage therapies for ophthalmic bacterial infections
Partnership leverages Locus's proprietary platform that integrates predictive artificial intelligence, high-throughput robotics, and synthetic biology to create therapeutic cocktails targeting antimicrobial-resistant eye infections
Frequently Asked Questions
Viatris's primary AI initiative is a research collaboration with Locus Biosciences to develop AI-powered bacteriophage therapies for ophthalmic infections, announced in October 2025.
Viatris appears to be in early stages of AI adoption, with limited AI mentions in earnings calls and primarily focusing on digital transformation and operational efficiency improvements.
There is no evidence of significant internal AI development. The company appears to rely on partnerships and external vendors for AI capabilities.
Currently, Viatris's main drug development AI application is through the Locus partnership for bacteriophage therapy development using AI, robotics, and synthetic biology.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| Real-World Evidence (RWE) Analytics | Not specified | Regulatory purposes and innovation, patient centricity, medicine regulation |
| Digital Employee Engagement Tools | Not specified | Remote work capabilities and employee connectivity during COVID-19 |
Sources
About Us | Viatris
Viatris AI Profile: Capabilities, IP and People - The AI Power Rankings
Viatris (VTRS) Is Up 5.1% After Announcing AI-Driven Phage Therapy Partnership
How COVID Accelerated the Digital Transformation at Viatris
Viatris Wins 2021 Global CPhI Pharma Award for Digital Innovation
Form 10-K Annual Report 2024
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.